ArticleProstate cancer and prostatic diseases2022

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer.

Charles G Drake et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.